NOTV

Inotiv, Inc. is a contract research company engaged in providing nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries and selling a range of research-quality animals and diets to the same industries, as well as academia and government clients. Its products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development. It operates through two segments: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through DSA segment, it supports the discovery, nonclinical development and clinical development needs of researchers and clinicians for primarily small molecule drug candidates, as well as biotherapeutics and biomedical devices. Through RMS segment, it offers access to a range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas.

Wall Street analysts forecast NOTV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NOTV is 5.00 USD with a low forecast of 5.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Inotiv Inc revenue for the last quarter amounts to 138.14M USD, increased 5.92 % YoY.

Inotiv Inc. EPS for the last quarter amounts to -0.25 USD, decreased -65.75 % YoY.

Inotiv Inc (NOTV) has 1945 emplpoyees as of January 10 2026.

Today NOTV has the market capitalization of 20.87M USD.